Browse the evidence

Single application of cooling has generally no effect on recovery during the 24–72 hour period following resistance and endurance exercises, though it may benefit neuromuscular function recovery 24–48 hours after sprint exercise.

If you have a competition or hard workout 24-72 hours later, cold water immersion after your initial session won't significantly help you recover from resistance or endurance training. It might help if you did sprint intervals, but don't rely on it for general late recovery.

Triple agonists (retatrutide, SAR441255) demonstrate superior efficacy in reversing fatty liver disease (MASH) compared to dual agonists and GLP-1 monotherapy.

For those with fatty liver disease (MASH), triple agonists like retatrutide have shown remarkable ability to normalize liver fat in 90% of patients in clinical trials. This makes them a promising treatment option for liver health, beyond just weight loss.

GLP-1 receptor agonists (Liraglutide and Exenatide) significantly improve menstrual frequency and ovulation rates in overweight/obese women with PCOS, primarily through weight loss and insulin resistance reduction rather than direct ovarian stimulation.

For overweight women with PCOS struggling with irregular periods, GLP-1 agonists like Liraglutide or Exenatide (often combined with Metformin) are effective treatments. They improve menstrual regularity and ovulation rates significantly better than Metformin alone. The benefits are largely driven by weight loss and reduced insulin resistance, but may also involve direct hormonal regulation. Consult a doctor for dosing, as injections are required for current FDA-approved versions.

Combining GLP-1 receptor agonists (Liraglutide or Exenatide) with Metformin significantly improves pregnancy rates and endometrial receptivity compared to Metformin monotherapy in women with PCOS undergoing IVF.

If you have PCOS, are overweight, and are struggling with infertility despite trying standard treatments like Clomiphene, ask your doctor about adding Liraglutide to your Metformin regimen before starting IVF. One study showed this combination significantly improved pregnancy rates per embryo transfer compared to Metformin alone. Note that these drugs are not approved for use during pregnancy, so a washout period is required.

Sustained remission of type 2 diabetes (via weight loss or bariatric surgery) reduces the risk of microvascular and macrovascular complications compared to standard care.

Achieving remission through sustained weight loss or surgery not only normalizes blood sugar but also significantly reduces your risk of heart disease, kidney damage, and eye problems over the long term. This benefit is likely greater than just controlling blood sugar with medication alone.

Higher dietary intake of polyunsaturated fatty acids (PUFAs) is associated with a lower risk of heart disease mortality in adults without prior myocardial infarction, whereas saturated (SFAs) and monounsaturated fatty acids (MUFAs) show no such association.

For heart health prevention, focus on increasing polyunsaturated fats (found in fish, nuts, seeds, and vegetable oils) rather than just cutting saturated fats. This benefit appears strongest for people who have not yet had a heart attack. If you have existing heart disease, dietary changes alone may not be sufficient to reduce mortality risk, and medical management is critical.

Liraglutide treatment is associated with decreased liver fibrosis in patients with type 2 diabetes, as evidenced by lower NAFLD fibrosis score (NFS), FIB-4, and liver stiffness measurement (LSM) after 12 months.

If you have Type 2 Diabetes, ask your doctor about Liraglutide. This medication has been shown to be associated with reduced markers of liver scarring (fibrosis) over a year of use. This is particularly relevant if you are at risk for Non-Alcoholic Fatty Liver Disease (NAFLD), which is common in T2DM. The benefit appears to be linked to its hormonal effects and weight loss.

Once-weekly subcutaneous semaglutide (up to 1.0 mg) in patients with type 2 diabetes produces significant weight loss (-4.69 kg at 6 months, -5.38 kg at 12 months) and improves metabolic parameters, but this weight loss is accompanied by a significant reduction in lean body mass (over 3 kg) that requires mitigation through nutritional education and structured exercise.

If you are using once-weekly semaglutide for Type 2 Diabetes, expect to lose about 5 kg of body weight over 6-12 months, along with improvements in blood sugar and blood pressure. However, this weight loss includes a significant loss of muscle mass (over 3 kg). To counteract this, you must actively engage in resistance exercise and follow a nutrition plan that prioritizes protein, as the medication alone will not preserve your muscle.

Patients using GLP-1 receptor agonists (GLP-1RA) for weight loss consistently fail to meet Dietary Reference Intakes (DRI) for key micronutrients (fiber, calcium, iron, magnesium, potassium, choline, vitamins A, C, D, E, K) and MyPlate food group servings (fruit, vegetables, grains, dairy).

If you are taking a GLP-1RA, your reduced appetite likely means you are not getting enough fiber, calcium, magnesium, and vitamins. You must actively track your food intake to ensure you are hitting micronutrient goals, as you cannot rely on feeling full. Focus on nutrient-dense foods and consider supplementation if dietary intake remains low, as standard portion sizes are likely insufficient.

GLP-1RA users often underconsume protein relative to their increased needs for preserving lean mass during rapid weight loss, despite protein percentage of calories being within the Acceptable Macronutrient Distribution Range (AMDR).

Even if your protein percentage looks fine, you are likely not eating enough grams of protein to protect your muscles while losing weight rapidly on GLP-1RA. Aim for 1.2-2.0 g of protein per kg of body weight daily. Prioritize lean protein sources in every small meal.

Initiating anti-obesity medications (AOMs) at the weight loss plateau (WLP) is more effective for achieving additional weight loss than waiting until significant weight regain occurs.

Do not wait for significant weight regain to seek help. If your weight stops dropping after surgery (plateau), discuss starting an anti-obesity medication immediately to maximize your results.

Precision nutrition, which tailors dietary interventions to individual genetic backgrounds, gut microbiota, and metabolic profiles, has the potential to transform obesity management by addressing interindividual variability in weight loss responses.

Instead of following generic diet advice that may not work for you, consider approaches that look at your specific body metrics, genetics, or gut health. While full genetic testing isn't always necessary or affordable, using metabolic profiles or simple clustering can help tailor your diet for better weight loss results. The key is personalization: what works for one person might not work for you, so finding a method that fits your unique biology is crucial for long-term success.

Partial ROM training performed at long muscle lengths (e.g., bottom half of a squat) may produce greater muscle hypertrophy than full ROM training.

If you are doing partial reps, ensure you are doing them at long muscle lengths (e.g., the bottom half of a squat). This specific variation may actually build muscle slightly better than full squats. Avoid partial reps at short muscle lengths (e.g., top half of a squat) if hypertrophy is your goal, as they offer no advantage over full ROM.

Dietary fibers, particularly soluble apple pectin, selectively reshape the gut microbiota of obese individuals by increasing beneficial bacteria (Megasphaera, Akkermansia) and reducing harmful ones (Acidaminococcus intestini), thereby improving metabolic health markers compared to lean profiles.

If you are obese, not all fibers are created equal for your gut health. Soluble fibers like apple pectin appear to specifically boost beneficial bacteria (like Akkermansia and Megasphaera) and reduce harmful ones in obese gut environments. Incorporating apple pectin or whole apples may be a more effective strategy for metabolic health than generic fiber supplements.

High intake of added fructose (from processed foods/beverages) is significantly associated with increased odds of metabolic syndrome in healthy adults, whereas high intake of natural fructose (from fruits/vegetables) is not.

Distinguish between your sources of sugar. The study links high intake of added fructose (found in processed foods and sweetened beverages) to a significantly higher risk of metabolic syndrome. However, high intake of natural fructose from whole foods like fruits and vegetables was not associated with this risk. Prioritize reducing added sugars from industrialized foods while maintaining fruit and vegetable intake.

Recreational athletes can maintain endurance and muscular strength performance on predominantly plant-based diets (whole food or meat alternatives) compared to an omnivorous diet, provided protein and carbohydrate intake meet standard sports nutrition recommendations.

If you are a recreational athlete, you do not need to eat meat to maintain your running speed or strength. You can switch to a whole-food plant-based diet or use plant-based meat alternatives (like Beyond or Impossible burgers) as long as you eat enough protein (0.8-1.2g/kg/day) and carbohydrates (3-5g/kg/day). Ensure you are eating enough total calories and maintaining your training routine.

Adopting 'Planeterranea' nutritional pyramids based on local foods provides the same health benefits as the Mediterranean Diet while addressing cultural, economic, and accessibility barriers.

You do not need to move to the Mediterranean to eat like one. Identify local foods that match the nutritional profile of the Mediterranean Diet (healthy fats, high fiber, low sugar) and build your meals around them. Use local oils, nuts, grains, and vegetables to create a 'Planeterranea' diet that is sustainable and culturally appropriate.

Newer diabetes medications, specifically GLP-1 receptor agonists (like tirzepatide) and SGLT2 inhibitors, facilitate diabetes remission through significant weight loss and glycemic control, though long-term remission data is still emerging.

Newer drugs like tirzepatide and GLP-1 agonists can achieve high remission rates (up to 81%) by combining weight loss with hormonal effects. However, they are expensive, require injections, and long-term remission data is still being gathered. They are a safer alternative to surgery for some, but not a guaranteed cure.

Supplements including MitoQ, urolithin A, omega-3 polyunsaturated fatty acids (n3-PUFAs), and GlyNAC improve physical function in older individuals through mechanisms involving mitochondrial biogenesis, bioenergetics, and quality control.

If you are older and find it difficult to maintain high levels of physical activity, consider discussing supplements like MitoQ, urolithin A, omega-3s, or GlyNAC with your healthcare provider. These may support muscle health and physical function by targeting mitochondrial efficiency, serving as a complement to whatever activity you can safely perform.

Nicotinamide adenine dinucleotide (NAD+) precursors may improve physical function in older individuals, but this outcome appears independent of changes in skeletal muscle mitochondrial function.

Some NAD+ precursors might help older adults improve physical function, but they likely do not work by fixing mitochondria. If you are using them, understand that their benefit may come from a different biological pathway than mitochondrial-targeting supplements.

In young adult men, a longer daily eating window is associated with higher insulin resistance (HOMA-IR) and a worse cardiometabolic risk score, while a shorter time from midsleep to first food intake (earlier eating) is associated with better cardiometabolic health.

For young men, how you time your food matters for metabolic health even if it doesn't change your weight. Try to keep your daily eating window shorter (avoid grazing all day) and eat your first meal closer to when you wake up. This pattern is linked to better insulin sensitivity and lower cardiometabolic risk.

Public perception of GLP-1 receptor agonists (GLP-1 RAs) on social media is predominantly neutral-to-positive, driven by reported weight loss efficacy and positive psychological impacts, despite awareness of side effects.

Social media discussions about GLP-1 drugs are largely positive, focusing on weight loss and mental health benefits, though side effects and access issues are common concerns. Patients should be aware that while public sentiment is favorable, individual experiences with side effects and availability vary significantly.

Myostatin-activin pathway inhibitors (MAPi), specifically bimagrumab, can reduce fat mass while preserving or increasing lean mass, offering a potential solution to the lean mass loss associated with GLP-1 agonists.

If you are concerned about losing muscle on weight loss drugs, ask your doctor about Myostatin-Activin Pathway Inhibitors (MAPi) like bimagrumab. In studies, this drug helped patients lose fat while actually gaining muscle. It is currently being studied in combination with GLP-1 drugs.

Combining GLP-1 receptor agonists with other Nutrient Stimulated Hormones (NuSH) like glucagon or amylin, or using dual/triple agonists like tirzepatide, may result in less lean mass loss compared to single-agonist GLP-1 treatments.

If you are on semaglutide and worried about muscle loss, ask your doctor if tirzepatide (a dual GLP-1/GIP drug) might be a better option for you, as it appears to spare more muscle. Newer triple-agonist drugs are also in development.